Facebook
Twitter
LinkedIn
ForwardRecertification (MOC) Review Course Webcast (2016): Penile / Urethral Cancer
The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically-specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam. Sample multiple choice practice questions as well as case based discussions and debates will be utilized to prepare attendees for the upcoming Recertification Examination.
Target Audience
This program is designed for:
- Practicing urologists preparing for the Recertification (MOC) Examination.
Learning Objectives
Upon completion of this webcast, participants will be able to:
- Review generally accepted urological practices for superior patient care
- Discuss a core knowledge of urology necessary for taking the Recertification Examination
- Examine the most recent changes and additions to the AUA guidelines
Faculty Disclosures:
Mohamad E. Allaf, MD: Nothing to disclose
Robert E. Brannigan, MD: The American Society for Reproductive Medicine (ASRM): Leadership Position, Health Publishing; The American Society for Reproductive Medicine: Leadership Position; AbbVie, Inc.: Other : Grant to Northwestern University, Feinberg School; The National Institutes of Health: Other : NIH/NICHD Data and
Safety Monitoring Board Member
Peter R. Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
Siamak Daneshmand, MD: Photocure: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Taris: Consultant or Advisor
Howard B. Goldman, MD, FACS: Allergan: Meeting Participant or Lecturer; Astellas; Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook Scientific Study or Trial; Pfizer: Consultant or Advisor, Meeting Participant or Lecturer; Axonics:Consultant or Advisor
Mantu Gupta, MD: Cook Urological: Meeting Participant or Lecturer; Boston Scientific: Meeting Participant or Lecturer
Badrinath R. Konety, MD, MBA: Axogen Inc.: Consultant or Advisor; Photocure Inc: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; Spectrum: Scientific Study or Trial
Kurt A. McCammon, MD: Urology Of Virginia: Leadership Position, Employee; AMS: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Astellas: Scientific Study or Trial; Allergan: Scientific Study or Trial; Solace: Scientific Study or Trial
Kevin T. McVary, MD, FACS: Astellas: Scientific Study or Trial; Lilly/ICOS: Consultant or Advisor, Scientific Study or Trial, Other; NIDDK: Scientific Study or Trial; AMS: Consultant or Advisor, Scientific Study or Trial; Sophris: Scientific Study or Trial
Aseem R. Shukla, MD: Nothing to disclose
Education Council Disclosures:
Timothy Charles Brand, MD: Nothing to Disclose
Peter Robert Carroll MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
Sam S. Chang, MD: Astellas Consultant or Advisor; NIH: Scientific Study or Trial; GLG: Consultant or Advisor; Janssen: Consultant or Advisor
Shelby Englert (OE Staff): Nothing to Disclose
Matthew Thomas Gettman, MD: Nothing to Disclose
Christina Giffin (OE Staff): Nothing to Disclose
Inderbir Singh Gill ,MD, MCh: Nothing to Disclose
William C. Hulbert Jr., MD: Nothing to Disclose
Douglas A. Husmann, MD: Nothing to Disclose
Brant Inman, MD, MS, FRCSC: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech Inc Scientific Study or Trial; Combat Medical Consultant or Advisor
Mark L. Jordan, MD, FACS: Nothing to disclose
Hari K. Koul, PhD: Novartis Pharmaceuticals: Consultant or Advisor; Urologic Research: Leadership Position;PLOS one: Leadership Position; OMICS group: Leadership Position, Open Access Publishing, Leadership Position, Health Publishing
Martin A. Koyle, MD: Nothing to Disclose
John Stephen Lam, MD: Nothing to Disclose
Gary Evan Lemack, MD: Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic Consultant or Advisor
Yair Lotan, MD: Abbott: Scientific Study or Trial; Danone: Consultant or Advisor, Scientific Study or Trial; Cepheid: Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor; Biocancell: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; Photocure: Scientific Study or Trial
Manoj Monga, MD: Fortec: Other; Endourology society: Leadership Position
Victor William Nitti, MD (OE Staff): Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial
Christopher Porter, MD: Genomic Health: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Gail S. Prins, PhD: Nothing to Disclose
Jay D. Raman, MD: American Kidney Stone Management: Investment Interest
Lee Richstone, MD Nothing to Disclose
Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
Karl-Dietrich Sievert, MD, PhD: AMS: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer
Joseph A. Smith Jr., MD: Nothing to Disclose
Edouard John Trabulsi, MD: GenomeDx: Consultant or Advisor
Method of Participation
To claim CME credit/hours of participation for each webcast, the learner must complete to pre-test, view the webcast, complete the posttest passing with 80% accuracy and submit the evaluation.
Estimated time to complete this activity: 0.75 hours
Release Date: September, 2016
Expiration Date: September, 2019
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 0.75 AMA PRA Category 1 Credit™
- 0.75 Non-Physician Participation